CEO SUMMARY: In September, Palmetto, a Medicare carrier serving California and seven other states, made public two draft local coverage determinations (LCDs) that revamp its coverage guidelines for molecular diagnostic tests (MDT) and laboratory-developed tests (LDT). All labs submitting claims to Palmetto would need to apply to Palmetto for each MDT or LDT it plans […]
Medicare Carrier Plans to Reject Molecular Claims
In February, Palmetto intends to cease accepting code-stacked molecular test claims
- By Robert Michel
- > From the Volume XVIII No. 15 - November 7, 2011 Issue
- Tags: cap, clinical lab, clinical lab fee schedule, clinical laboratories, clinical labs, companion diagnostic, Companion diagnostics, cpt, cpt code, current procedural terminology, Diagnostic tests, genetic test, genetic testing, genetic tests, impac, lab test, lab test cost, lab test costs, lab tests, laboratories, Laboratory Developed Test (LDT), laboratory director, laboratory medicine, laboratory test, laboratory testing, laboratory tests, ldt, local coverage determination, local coverage determinations, Medicare, Medicare Administrative Contractor, molecular assay, molecular assays, molecular diagnostic, molecular diagnostic test, molecular diagnostic tests, molecular pathology, molecular tests, new diagnostic technologies, pathologists, pathology coding, Pathology group, pathology groups, personalized medicine, private payer, rina wolf, xifin
